The Priority Review

Approvals Brief

FDA approves giredestrant with everolimus for ESR1-mutated breast cancer

On November 16, 2026 the FDA approved giredestrant (Wilserdly) in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. The approval includes the FoundationOne Liquid CDx assay as a companion diagnostic to identify ESR1 mutations.

Primary source

FDA approval notification, November 16, 2026

FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer

Read the source: FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer fda.gov

Machine-summarized from the source above; not independently reported. How we use automation